Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis
- 1 August 1999
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 5 (4) , 268-272
- https://doi.org/10.1177/135245859900500413
Abstract
Disease progression and irreversible disability in multiple sclerosis results from incomplete recovery from relapses, but most importantly from insidious disease progression. Although magnetic resonance imaging parameters, such as new lesion rate and gadolinium enhancement, reflect inflammation and disease activity they have no bearing on disease progression. Until now the T2 lesion load or disease burden has been relied upon for this, despite its poor relationship with disability measures. This paper looks at the mechanisms responsible for disease progression and discusses the MR techniques now available to reflect these pathological processes.Keywords
This publication has 38 references indexed in Scilit:
- Gene therapy for neurological disorders and brain tumors. By E. Antonio Chiocca and Xandra O. Breakefield, Totowa, NJ, Humana Press, 1998 458 pp, illustrated $135.00Annals of Neurology, 1998
- Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniquesJournal of Neurology, Neurosurgery & Psychiatry, 1998
- Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosisAnnals of Neurology, 1998
- Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesionsMagnetic Resonance Imaging, 1997
- Primary progressive multiple sclerosisBrain, 1997
- Lesion volume measurement in multiple sclerosis: How important is accurate repositioning?Journal of Magnetic Resonance Imaging, 1996
- Intra- and inter-observer agreement of brain MRI lesion volume measurements in multiple sclerosisBrain, 1995
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995
- Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosisAnnals of Neurology, 1994
- Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-upBrain, 1993